# Trade Mark Journal No.2026/007 13 February 2026

## WO0000001898575 (5)

Office of origin: United States of America

Date of International Registration:8 September 2025
Date of designation in the UK: 8 September 2025

International priority date claimed: 5 September 2025 (United States of America) (99376563)

Class 5
  Pharmaceutical preparations for treating diabetes; medical treatments in the nature of anti-diabetic pharmaceuticals; cell therapy for medical or veterinary use.

Vertex Pharmaceuticals Incorporated

Representative: Sarah Anne Keefe Womble Bond Dickinson (US) LLP, 470 Atlantic Avenue, Suite 600, Boston MA 02210, UNITED STATES OF AMERICA